{"transactions":[{"id":701464,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":28024,"kind":"person","name":"Quartel Adrian W","position":1,"cik":"0001910132","reported_name":"Quartel Adrian W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-29T20:10:50.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":13000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of restricted stock units (\"RSUs\") will vest on June 15, 2027.  25% of the total number of RSUs will vest on each of June 15, 2028, June 15, 2029 and June 15, 2030, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the total number of restricted stock units (\"RSUs\") will vest on June 15, 2027.  25% of the total number of RSUs will vest on each of June 15, 2028, June 15, 2029 and June 15, 2030, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."}],"balance_after":13000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":13000},"source":{"system":"sec-edgar","filing":"0001910132-26-000007","document":"form4-07292026_080746.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000191013226000007/form4-07292026_080746.xml","form_type":"4"}},{"id":711921,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-07-09T20:15:05.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":266,"price":4.5305,"value":1205.113,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":19270,"source":{"system":"sec-edgar","filing":"0001903669-26-000006","document":"form4-07092026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366926000006/form4-07092026_040701.xml","form_type":"4"}},{"id":763767,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-26T20:30:37.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":1700,"derivative":{"exercise_price":52.7,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001238403-26-000002","document":"form4-05262026_040510.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840326000002/form4-05262026_040510.xml","form_type":"4"}},{"id":763766,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-26T20:30:33.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":1700,"derivative":{"exercise_price":52.7,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001822557-26-000002","document":"form4-05262026_040508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255726000002/form4-05262026_040508.xml","form_type":"4"}},{"id":763764,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-26T20:30:31.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":1700,"derivative":{"exercise_price":52.7,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001240122-26-000002","document":"form4-05262026_040505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012226000002/form4-05262026_040505.xml","form_type":"4"}},{"id":763763,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44225,"kind":"person","name":"Barretto-Ko Percival","position":1,"cik":"0001978654","reported_name":"Barretto-Ko Percival","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-26T20:30:29.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":1700,"derivative":{"exercise_price":52.7,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001978654-26-000002","document":"form4-05262026_040503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000197865426000002/form4-05262026_040503.xml","form_type":"4"}},{"id":764138,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44301,"kind":"person","name":"Walbert Keli","position":1,"cik":"0002051489","reported_name":"Walbert Keli","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-26T20:30:16.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":1700,"derivative":{"exercise_price":52.7,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0002051489-26-000002","document":"form4-05262026_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051489/000205148926000002/form4-05262026_040512.xml","form_type":"4"}},{"id":853536,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":62015,"kind":"person","name":"Hooks Corwin Dale","position":1,"cik":"0001665347","reported_name":"Hooks Corwin Dale","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-09T20:08:18.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of restricted stock units (\"RSUs\") will vest on March 15, 2027.  25% of the total number of RSUs will vest on each of March 15, 2028, March 15, 2029 and March 15, 2030, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"25% of the total number of restricted stock units (\"RSUs\") will vest on March 15, 2027.  25% of the total number of RSUs will vest on each of March 15, 2028, March 15, 2029 and March 15, 2030, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."}],"balance_after":11000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001665347-26-000006","document":"form4-03092026_080309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000166534726000006/form4-03092026_080309.xml","form_type":"4"}},{"id":934731,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":69104,"kind":"person","name":"Ways Douglas Kirk","position":1,"cik":"0001869391","reported_name":"Ways Douglas Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T16:04:35.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F3","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":169.5,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001869391-26-000007","document":"form4-01212026_090131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1869391/000186939126000007/form4-01212026_090131.xml","form_type":"4"}},{"id":934730,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":69104,"kind":"person","name":"Ways Douglas Kirk","position":1,"cik":"0001869391","reported_name":"Ways Douglas Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T16:04:35.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":400,"derivative":{"exercise_price":104.13,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001869391-26-000007","document":"form4-01212026_090131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1869391/000186939126000007/form4-01212026_090131.xml","form_type":"4"}},{"id":934729,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":69104,"kind":"person","name":"Ways Douglas Kirk","position":1,"cik":"0001869391","reported_name":"Ways Douglas Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T16:04:35.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":266,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F3","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":791.25,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":266},"source":{"system":"sec-edgar","filing":"0001869391-26-000007","document":"form4-01212026_090131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1869391/000186939126000007/form4-01212026_090131.xml","form_type":"4"}},{"id":934728,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":69104,"kind":"person","name":"Ways Douglas Kirk","position":1,"cik":"0001869391","reported_name":"Ways Douglas Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-21T16:04:35.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":266,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":266,"derivative":{"exercise_price":104.13,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":266},"source":{"system":"sec-edgar","filing":"0001869391-26-000007","document":"form4-01212026_090131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1869391/000186939126000007/form4-01212026_090131.xml","form_type":"4"}},{"id":934727,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":69104,"kind":"person","name":"Ways Douglas Kirk","position":1,"cik":"0001869391","reported_name":"Ways Douglas Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-21T16:04:35.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of restricted stock units (\"RSUs\") vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the total number of restricted stock units (\"RSUs\") vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."}],"balance_after":3750,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001869391-26-000007","document":"form4-01212026_090131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1869391/000186939126000007/form4-01212026_090131.xml","form_type":"4"}},{"id":934726,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":69104,"kind":"person","name":"Ways Douglas Kirk","position":1,"cik":"0001869391","reported_name":"Ways Douglas Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-21T16:04:35.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of restricted stock units (\"RSUs\") vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the total number of restricted stock units (\"RSUs\") vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001869391-26-000007","document":"form4-01212026_090131.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1869391/000186939126000007/form4-01212026_090131.xml","form_type":"4"}},{"id":934725,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":69104,"kind":"person","name":"Ways Douglas Kirk","position":1,"cik":"0001869391","reported_name":"Ways Douglas Kirk","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-21T16:04:35.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":true,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the total number of restricted stock units (\"RSUs\") vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001869391-26-000007","document":"form4-01212026_090131.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1869391/000186939126000007/form4-01212026_090131.xml","form_type":"4"}},{"id":952077,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2026-01-05T21:43:53.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":4690,"price":4.5305,"value":21248.045,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired by the Reporting Person pursuant to the Issuer's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).  The Reporting Person acquired the maximum shares allowable pursuant to Section 423 of the Internal Revenue Code."}],"balance_after":19004,"source":{"system":"sec-edgar","filing":"0001903669-26-000002","document":"form4-01052026_090149.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366926000002/form4-01052026_090149.xml","form_type":"4"}},{"id":965056,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Restricted Stock Units","published_at":"2025-12-17T21:58:51.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares."}],"balance_after":1027,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":513},"source":{"system":"sec-edgar","filing":"0001533302-25-000011","document":"form4-12172025_091247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000011/form4-12172025_091247.xml","form_type":"4"}},{"id":965055,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Restricted Stock Units","published_at":"2025-12-17T21:58:51.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178\nshares withheld for taxes, resulting in a net issuance of 318 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178\nshares withheld for taxes, resulting in a net issuance of 318 shares."}],"balance_after":497,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":496},"source":{"system":"sec-edgar","filing":"0001533302-25-000011","document":"form4-12172025_091247.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000011/form4-12172025_091247.xml","form_type":"4"}},{"id":965054,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-17T21:58:51.000Z","date":"2025-12-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":184,"price":80.67,"value":14843.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares."}],"balance_after":8263,"source":{"system":"sec-edgar","filing":"0001533302-25-000011","document":"form4-12172025_091247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000011/form4-12172025_091247.xml","form_type":"4"}},{"id":965053,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-17T21:58:51.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 4,106 RSUs. 50% or 2,053 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 2,053 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 513 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 329 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":8447,"source":{"system":"sec-edgar","filing":"0001533302-25-000011","document":"form4-12172025_091247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000011/form4-12172025_091247.xml","form_type":"4"}},{"id":965052,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-17T21:58:51.000Z","date":"2025-12-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":178,"price":80.67,"value":14359.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178\nshares withheld for taxes, resulting in a net issuance of 318 shares."}],"balance_after":7934,"source":{"system":"sec-edgar","filing":"0001533302-25-000011","document":"form4-12172025_091247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000011/form4-12172025_091247.xml","form_type":"4"}},{"id":965051,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-17T21:58:51.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 1,986 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 496 RSUs vested, with 178\nshares withheld for taxes, resulting in a net issuance of 318 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":8112,"source":{"system":"sec-edgar","filing":"0001533302-25-000011","document":"form4-12172025_091247.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000011/form4-12172025_091247.xml","form_type":"4"}},{"id":965350,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":1196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares."}],"balance_after":2392,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1196},"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":965349,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":false,"shares":1480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares."}],"balance_after":1480,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1480},"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":965348,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). 50% or 1,666 shares of the total shares vested on November 26, 2023.  50% or 1,666 shares of the total shares did not vest as the relevant performance goal was not achieved."}],"balance_after":0,"derivative":{"exercise_price":344.25,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":965347,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":1666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). 50% or 1,666 shares of the total shares vested on November 26, 2023.  50% or 1,666 shares of the total shares did not vest as the relevant performance goal was not achieved."}],"balance_after":1666,"derivative":{"exercise_price":104.13,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":965346,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":608,"price":80.67,"value":49047.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares."}],"balance_after":14314,"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":965345,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":1196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":14922,"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":965344,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":752,"price":80.67,"value":60663.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares."}],"balance_after":13726,"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":965343,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-17T21:56:43.000Z","date":"2025-12-15","kind":"exercise","planned":false,"acquired":true,"shares":1480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units (\"RSUs\"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the \"Annual Vesting Date\") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":14478,"source":{"system":"sec-edgar","filing":"0001903669-25-000010","document":"form4-12172025_091239.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000010/form4-12172025_091239.xml","form_type":"4"}},{"id":969487,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":169.5,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969486,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":400,"derivative":{"exercise_price":104.13,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969485,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":88,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1143,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":88},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969484,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":88,"derivative":{"exercise_price":104.13,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":88},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969483,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":458,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":564,"expiration_date":"2030-09-08","underlying":"Common Stock","underlying_shares":458},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969482,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":34781,"kind":"person","name":"SPIEGELMAN DANIEL K","position":1,"cik":"0001238403","reported_name":"SPIEGELMAN DANIEL K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-16T00:00:01.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":458,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":458,"derivative":{"exercise_price":104.13,"expiration_date":"2030-09-08","underlying":"Common Stock","underlying_shares":458},"source":{"system":"sec-edgar","filing":"0001238403-25-000007","document":"form4-12152025_111257.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000123840325000007/form4-12152025_111257.xml","form_type":"4"}},{"id":969461,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":169.5,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969460,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":400,"derivative":{"exercise_price":104.13,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969459,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":666,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":0,"derivative":{"exercise_price":186,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":666},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969458,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":666,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":666,"derivative":{"exercise_price":104.13,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":666},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969457,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":133,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1143,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969456,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":133,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":133,"derivative":{"exercise_price":104.13,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969455,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1499,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":230.25,"expiration_date":"2030-08-06","underlying":"Common Stock","underlying_shares":1499},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969454,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":1499,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":1499,"derivative":{"exercise_price":104.13,"expiration_date":"2030-08-06","underlying":"Common Stock","underlying_shares":1499},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969453,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1255,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":123,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":1255},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969452,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":1255,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":1255,"derivative":{"exercise_price":104.13,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":1255},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969451,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":387,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":108,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":387},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969450,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":24548,"kind":"person","name":"GREY MICHAEL G","position":1,"cik":"0001240122","reported_name":"GREY MICHAEL G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:58:00.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":387,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":387,"derivative":{"exercise_price":104.13,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":387},"source":{"system":"sec-edgar","filing":"0001240122-25-000009","document":"form4-12152025_111256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000124012225000009/form4-12152025_111256.xml","form_type":"4"}},{"id":969481,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":933,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares vest on a monthly basis from January 3, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":0,"derivative":{"exercise_price":344.25,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":933},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969480,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":933,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares vest on a monthly basis from January 3, 2022, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":933,"derivative":{"exercise_price":104.13,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":933},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969479,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1933,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":0,"derivative":{"exercise_price":186,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":1933},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969478,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":1933,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares vest on a monthly basis from December 16, 2021, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":1933,"derivative":{"exercise_price":104.13,"expiration_date":"2031-12-15","underlying":"Common Stock","underlying_shares":1933},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969477,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1506,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":733},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969476,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":733,"derivative":{"exercise_price":104.13,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":733},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969475,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":953,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":230.25,"expiration_date":"2030-08-06","underlying":"Common Stock","underlying_shares":953},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969474,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":953,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":953,"derivative":{"exercise_price":104.13,"expiration_date":"2030-08-06","underlying":"Common Stock","underlying_shares":953},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969473,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1579,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":123,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":1579},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969472,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:54:50.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":1579,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":1579,"derivative":{"exercise_price":104.13,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":1579},"source":{"system":"sec-edgar","filing":"0001533302-25-000009","document":"form4-12152025_111246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000009/form4-12152025_111246.xml","form_type":"4"}},{"id":969692,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-15T23:52:04.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vested on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":0,"derivative":{"exercise_price":344.25,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001903669-25-000008","document":"form4-12152025_111200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000008/form4-12152025_111200.xml","form_type":"4"}},{"id":969691,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-12-15T23:52:04.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest over a four-year period commencing January 3, 2022, with 1/4th of the shares vested on January 3, 2023 and 1/36th of the remaining shares vesting on a monthly basis, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan)."}],"balance_after":10000,"derivative":{"exercise_price":104.13,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001903669-25-000008","document":"form4-12152025_111200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000008/form4-12152025_111200.xml","form_type":"4"}},{"id":969471,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":169.5,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969470,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":400,"derivative":{"exercise_price":104.13,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969469,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":133,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1143,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969468,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":133,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":133,"derivative":{"exercise_price":104.13,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":133},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969467,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":362,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":230.25,"expiration_date":"2030-08-06","underlying":"Common Stock","underlying_shares":362},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969466,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":362,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":362,"derivative":{"exercise_price":104.13,"expiration_date":"2030-08-06","underlying":"Common Stock","underlying_shares":362},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969465,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":309,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":123,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":309},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969464,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":309,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":309,"derivative":{"exercise_price":104.13,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":309},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969463,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":173,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":108,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969462,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44226,"kind":"person","name":"SIMPSON CAMILLA V","position":1,"cik":"0001822557","reported_name":"SIMPSON CAMILLA V","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:50:10.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":173,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":173,"derivative":{"exercise_price":104.13,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":173},"source":{"system":"sec-edgar","filing":"0001822557-25-000007","document":"form4-12152025_111206.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000182255725000007/form4-12152025_111206.xml","form_type":"4"}},{"id":969446,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44225,"kind":"person","name":"Barretto-Ko Percival","position":1,"cik":"0001978654","reported_name":"Barretto-Ko Percival","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:47:38.000Z","date":"2025-12-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":800,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of May 25, 2023, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":0,"derivative":{"exercise_price":169.5,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001978654-25-000003","document":"form4-12152025_111234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000197865425000003/form4-12152025_111234.xml","form_type":"4"}},{"id":969445,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44225,"kind":"person","name":"Barretto-Ko Percival","position":1,"cik":"0001978654","reported_name":"Barretto-Ko Percival","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:47:38.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":800,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Effective August 4, 2025, the Issuer effected a reverse stock split (the \"Reverse Split\") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on December 11, 2025 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of May 25, 2023, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":800,"derivative":{"exercise_price":104.13,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001978654-25-000003","document":"form4-12152025_111234.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000197865425000003/form4-12152025_111234.xml","form_type":"4"}},{"id":969786,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":44301,"kind":"person","name":"Walbert Keli","position":1,"cik":"0002051489","reported_name":"Walbert Keli","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-15T23:46:09.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":3400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the \"Plan\") through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan)."}],"balance_after":3400,"derivative":{"exercise_price":88.41,"expiration_date":"2035-12-10","underlying":"Common Stock","underlying_shares":3400},"source":{"system":"sec-edgar","filing":"0002051489-25-000007","document":"form4-12152025_111205.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2051489/000205148925000007/form4-12152025_111205.xml","form_type":"4"}},{"id":971198,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Restricted Stock Units","published_at":"2025-12-13T00:05:39.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":false,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares."}],"balance_after":5700,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1900},"source":{"system":"sec-edgar","filing":"0001533302-25-000007","document":"form4-12132025_121236.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000007/form4-12132025_121236.xml","form_type":"4"}},{"id":971197,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Restricted Stock Units","published_at":"2025-12-13T00:05:39.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":7600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares."}],"balance_after":7600,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":7600},"source":{"system":"sec-edgar","filing":"0001533302-25-000007","document":"form4-12132025_121236.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000007/form4-12132025_121236.xml","form_type":"4"}},{"id":971196,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Restricted Stock Units","published_at":"2025-12-13T00:05:39.000Z","date":"2025-12-10","kind":"exercise","planned":false,"acquired":false,"shares":514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares."}],"balance_after":1539,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":514},"source":{"system":"sec-edgar","filing":"0001533302-25-000007","document":"form4-12132025_121236.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000007/form4-12132025_121236.xml","form_type":"4"}},{"id":971195,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-13T00:05:39.000Z","date":"2025-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":680,"price":88.41,"value":60118.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares."}],"balance_after":7616,"source":{"system":"sec-edgar","filing":"0001533302-25-000007","document":"form4-12132025_121236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000007/form4-12132025_121236.xml","form_type":"4"}},{"id":971194,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-13T00:05:39.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":true,"shares":1900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 1,900 shares vested and 680 shares were withheld for taxes, resulting in a net issuance of 1,220 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."}],"balance_after":8296,"source":{"system":"sec-edgar","filing":"0001533302-25-000007","document":"form4-12132025_121236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000007/form4-12132025_121236.xml","form_type":"4"}},{"id":971193,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-13T00:05:39.000Z","date":"2025-12-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":184,"price":85.67,"value":15763.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares."}],"balance_after":6396,"source":{"system":"sec-edgar","filing":"0001533302-25-000007","document":"form4-12132025_121236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000007/form4-12132025_121236.xml","form_type":"4"}},{"id":971192,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-12-13T00:05:39.000Z","date":"2025-12-10","kind":"exercise","planned":false,"acquired":true,"shares":514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 2,053 RSU's. Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective. 25% of the total number of the RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 514 shares vested and 184 shares were withheld for taxes, resulting in a net issuance of 330 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."}],"balance_after":6580,"source":{"system":"sec-edgar","filing":"0001533302-25-000007","document":"form4-12132025_121236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000007/form4-12132025_121236.xml","form_type":"4"}},{"id":971437,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-12-13T00:03:14.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":false,"shares":4950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares."}],"balance_after":14850,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4950},"source":{"system":"sec-edgar","filing":"0001903669-25-000006","document":"form4-12132025_121210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000006/form4-12132025_121210.xml","form_type":"4"}},{"id":971436,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-12-13T00:03:14.000Z","date":"2025-12-11","kind":"grant","planned":false,"acquired":true,"shares":19800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares."}],"balance_after":19800,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":19800},"source":{"system":"sec-edgar","filing":"0001903669-25-000006","document":"form4-12132025_121210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000006/form4-12132025_121210.xml","form_type":"4"}},{"id":971435,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-12-13T00:03:14.000Z","date":"2025-12-10","kind":"exercise","planned":false,"acquired":false,"shares":1196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's.  Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective.  25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's.  Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective.  25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares."}],"balance_after":3588,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1196},"source":{"system":"sec-edgar","filing":"0001903669-25-000006","document":"form4-12132025_121210.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000006/form4-12132025_121210.xml","form_type":"4"}},{"id":971434,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-13T00:03:14.000Z","date":"2025-12-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":2194,"price":88.41,"value":193971.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares."}],"balance_after":12998,"source":{"system":"sec-edgar","filing":"0001903669-25-000006","document":"form4-12132025_121210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000006/form4-12132025_121210.xml","form_type":"4"}},{"id":971433,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-13T00:03:14.000Z","date":"2025-12-11","kind":"exercise","planned":false,"acquired":true,"shares":4950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"25% of the total number of RSUs vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date. On December 11, 2025, 4,950 shares vested and 2,194 shares were withheld for taxes, resulting in a net issuance of 2,756 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."}],"balance_after":15192,"source":{"system":"sec-edgar","filing":"0001903669-25-000006","document":"form4-12132025_121210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000006/form4-12132025_121210.xml","form_type":"4"}},{"id":971432,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-13T00:03:14.000Z","date":"2025-12-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":428,"price":85.67,"value":36666.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's.  Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective.  25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares."}],"balance_after":10242,"source":{"system":"sec-edgar","filing":"0001903669-25-000006","document":"form4-12132025_121210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000006/form4-12132025_121210.xml","form_type":"4"}},{"id":971431,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-12-13T00:03:14.000Z","date":"2025-12-10","kind":"exercise","planned":false,"acquired":true,"shares":1196,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted a total of 4,784 RSU's.  Subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date, 25% of the total number of RSUs vested on December 10, 2025, the first anniversary of the achievement of a specified clinical development objective.  25% of the total number of RSUs will vest on each of the second, third and fourth anniversaries of such achievement.  On December 10, 2025, 1,196 shares vested and 428 shares were withheld for taxes, resulting in a net issuance of 768 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of SPRB common stock."}],"balance_after":10670,"source":{"system":"sec-edgar","filing":"0001903669-25-000006","document":"form4-12132025_121210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000006/form4-12132025_121210.xml","form_type":"4"}},{"id":1014691,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Restricted Stock Units","published_at":"2025-10-22T20:15:07.000Z","date":"2025-10-20","kind":"exercise","planned":false,"acquired":false,"shares":2053,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\")  represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 2,053\n performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 2,053\n performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2053},"source":{"system":"sec-edgar","filing":"0001533302-25-000004","document":"form4-10222025_041003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000004/form4-10222025_041003.xml","form_type":"4"}},{"id":1014690,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Restricted Stock Units","published_at":"2025-10-22T20:15:07.000Z","date":"2025-10-20","kind":"grant","planned":false,"acquired":true,"shares":2053,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\")  represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 2,053\n performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 2,053\n performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares."}],"balance_after":2053,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2053},"source":{"system":"sec-edgar","filing":"0001533302-25-000004","document":"form4-10222025_041003.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000004/form4-10222025_041003.xml","form_type":"4"}},{"id":1014689,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-10-22T20:15:07.000Z","date":"2025-10-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":661,"price":148.16,"value":97933.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 2,053\n performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares."}],"balance_after":6066,"source":{"system":"sec-edgar","filing":"0001533302-25-000004","document":"form4-10222025_041003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000004/form4-10222025_041003.xml","form_type":"4"}},{"id":1014688,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":71314,"kind":"person","name":"Gharib Samir M.","position":1,"cik":"0001533302","reported_name":"Gharib Samir M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CFO"}}],"security":"Common Stock","published_at":"2025-10-22T20:15:07.000Z","date":"2025-10-20","kind":"exercise","planned":false,"acquired":true,"shares":2053,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 2,053\n performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 661 shares were withheld for taxes, resulting in a net issuance of 1,392 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\")  represents a contingent right to receive one share of SPRB common stock."}],"balance_after":6727,"source":{"system":"sec-edgar","filing":"0001533302-25-000004","document":"form4-10222025_041003.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000153330225000004/form4-10222025_041003.xml","form_type":"4"}},{"id":1014840,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-10-22T20:15:05.000Z","date":"2025-10-20","kind":"exercise","planned":false,"acquired":false,"shares":4784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\")  represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4784},"source":{"system":"sec-edgar","filing":"0001903669-25-000003","document":"form4-10222025_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000003/form4-10222025_041001.xml","form_type":"4"}},{"id":1014839,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Restricted Stock Units","published_at":"2025-10-22T20:15:05.000Z","date":"2025-10-20","kind":"grant","planned":false,"acquired":true,"shares":4784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\")  represents a contingent right to receive one share of SPRB common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares."}],"balance_after":4784,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4784},"source":{"system":"sec-edgar","filing":"0001903669-25-000003","document":"form4-10222025_041001.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000003/form4-10222025_041001.xml","form_type":"4"}},{"id":1014838,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-10-22T20:15:05.000Z","date":"2025-10-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":1539,"price":148.16,"value":228018.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares."}],"balance_after":9474,"source":{"system":"sec-edgar","filing":"0001903669-25-000003","document":"form4-10222025_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000003/form4-10222025_041001.xml","form_type":"4"}},{"id":1014837,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":31240,"kind":"person","name":"Szwarcberg Javier B.","position":1,"cik":"0001903669","reported_name":"Szwarcberg Javier B.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF EXECUTIVE OFFICER"}}],"security":"Common Stock","published_at":"2025-10-22T20:15:05.000Z","date":"2025-10-20","kind":"exercise","planned":false,"acquired":true,"shares":4784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 14, 2024, the Reporting Person was granted 4,784 performance-based RSUs. On October 20, 2025, the Issuer's Board of Directors certified that certain specified performance goals were met and all of the RSUs vested. 1,539 shares were withheld for taxes, resulting in a net issuance of 3,245 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (\"RSU\")  represents a contingent right to receive one share of SPRB common stock."}],"balance_after":11013,"source":{"system":"sec-edgar","filing":"0001903669-25-000003","document":"form4-10222025_041001.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1903669/000190366925000003/form4-10222025_041001.xml","form_type":"4"}},{"id":1018757,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":74272,"kind":"organization","name":"Parkman Healthcare Partners LLC","position":1,"cik":"0001777015","reported_name":"Parkman Healthcare Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74273,"kind":"person","name":"Martinez Gregory","position":2,"cik":"0002091748","reported_name":"Martinez Gregory","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2025-10-15T16:32:43.000Z","date":"2025-10-06","kind":"sale","planned":false,"acquired":false,"shares":25,"price":17.4557,"value":436.3925,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $17.44 to $17.56. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1050,"source":{"system":"sec-edgar","filing":"0000919574-25-006126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2091748/000091957425006126/ownership.xml","form_type":"4"}},{"id":1018756,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":74272,"kind":"organization","name":"Parkman Healthcare Partners LLC","position":1,"cik":"0001777015","reported_name":"Parkman Healthcare Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74273,"kind":"person","name":"Martinez Gregory","position":2,"cik":"0002091748","reported_name":"Martinez Gregory","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2025-10-15T16:32:43.000Z","date":"2025-10-06","kind":"sale","planned":false,"acquired":false,"shares":232,"price":19.3264,"value":4483.7248,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $19.125 to $19.63. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1075,"source":{"system":"sec-edgar","filing":"0000919574-25-006126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2091748/000091957425006126/ownership.xml","form_type":"4"}},{"id":1018755,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":74272,"kind":"organization","name":"Parkman Healthcare Partners LLC","position":1,"cik":"0001777015","reported_name":"Parkman Healthcare Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74273,"kind":"person","name":"Martinez Gregory","position":2,"cik":"0002091748","reported_name":"Martinez Gregory","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2025-10-15T16:32:43.000Z","date":"2025-10-06","kind":"purchase","planned":false,"acquired":true,"shares":256,"price":17.9108,"value":4585.1648,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $17.55 to $18. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1307,"source":{"system":"sec-edgar","filing":"0000919574-25-006126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2091748/000091957425006126/ownership.xml","form_type":"4"}},{"id":1021466,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":74272,"kind":"organization","name":"Parkman Healthcare Partners LLC","position":1,"cik":"0001777015","reported_name":"Parkman Healthcare Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2025-10-09T00:55:08.000Z","date":"2025-10-06","kind":"sale","planned":false,"acquired":false,"shares":25,"price":17.4557,"value":436.3925,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $17.44 to $17.56. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1050,"source":{"system":"sec-edgar","filing":"0000919574-25-006012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000091957425006012/ownership.xml","form_type":"4"}},{"id":1021465,"issuer":{"id":6471,"kind":"organization","name":"SPRUCE BIOSCIENCES, INC."},"owners":[{"id":74272,"kind":"organization","name":"Parkman Healthcare Partners LLC","position":1,"cik":"0001777015","reported_name":"Parkman Healthcare Partners LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2025-10-09T00:55:08.000Z","date":"2025-10-06","kind":"sale","planned":false,"acquired":false,"shares":232,"price":19.3264,"value":4483.7248,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions within the range of $19.125 to $19.63. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The amount reported represents the Reporting Persons' pecuniary interest held through an investment in private funds. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose."}],"balance_after":1075,"source":{"system":"sec-edgar","filing":"0000919574-25-006012","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1683553/000091957425006012/ownership.xml","form_type":"4"}}],"next_cursor":"2025-10-09T00:55:08.000000Z,1021465"}